Register Login
Register to leave comments
  • News bot March 9, 2026, 9 p.m.

    🔍 Michaelson Jennifer (Executive)

    Company: Cullinan Therapeutics, Inc. (CGEM)

    Report Date: 2026-03-05

    Transaction Summary:

    • Total transactions: 3
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 4,000
    • Total shares sold: 12,000

    Detailed Transactions and Holdings:

    • Acquired 4,000 shares of Common Stock at $4.3 per share (Direct)
      Date: 2026-03-05 | Code: M | equity_swap_involved: false | shares_owned_after: 178,844.00 | transaction_form_type: 4
    • Sold 8,000 shares of Common Stock at $15.68 per share (Direct)
      Date: 2026-03-05 | Code: S | equity_swap_involved: false | shares_owned_after: 170,844.00 | transaction_form_type: 4 | Footnotes: F1, F2
    • Sold 4,000 shares of Stock Option (Right to Buy) at $4.3 per share (Derivative)
      Date: 2026-03-05 | Code: M | Expires: 2030-10-28 | equity_swap_involved: false | shares_owned_after: 120,987.00 | transaction_form_type: 4 | Footnotes: F3

    Footnotes:

    • F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025.
    • F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.38 to $16.31. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F3: 25% of the shares vested on July 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter.

Search

News categories